News

Access and download our newsletters from the Newsletter Archive

 
 

As well as keeping you up to date with the latest developments within the life sciences sector, Bionow members can also post updates to the Bionow News page to promote themselves to over 300 Bionow member organisations and the UK Life Sciences sector.

Whether currently a member or not, keep up to date with all the latest news and events by registering to receive the Bionow newsletter.

BioTryp Therapeutics Raises Pre-Seed Funding to advance its novel biofilm-inhibi...

Sep 20th 2024
Cambridge, UK: BioTryp Therapeutics, an award-winning drug discovery spin-out from the University of Cambridge, has raised £300k in pre-seed funding to advance the development of its novel ...
Read More

CF AMR Syndicate Launches £3 million Collaborative Discovery Programme

Mar 16th 2023
Funding New Antimicrobials to Treat Lung Infections in People with Cystic Fibrosis
Read More

£1.3M to develop new inhaled drug delivery platforms to treat viral and bacteri...

Mar 8th 2022
The University of Liverpool in partnership with the Liverpool School of Tropical Medicine have joined forces on a £1.3million research project to develop new inhaled drug delivery platforms...
Read More

iiCON partnership develops new organoid infection model to replicate impact of r...

Jul 5th 2021
A new experimental model that more accurately replicates the impact of respiratory infections on the lungs and upper airways has been developed through an industry academic partnership suppo...
Read More

F2G Closes US$60.8 Million Financing to fund late stage development of novel mec...

Aug 12th 2020
Financing round led by Cowen Healthcare Investments with strong support from existing investors Novo Holdings, Morningside Ventures, Brace Pharma Capital and Advent Life Sciences
Read More

F2G’s olorofim receives both FDA Orphan Drug Designation for Coccidioidomycosi...

Jun 10th 2020
F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, announced today that following the granting of Breakthrough Therapy desig...
Read More

F2G Receives US FDA Orphan Drug Designation for Olorofim

Mar 11th 2020
F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, announced today that the U.S. Food and Drug Administration (FDA) has gran...
Read More

F2G Receives US FDA Breakthrough Therapy Designation for Olorofim

Nov 11th 2019
F2G Ltd, a UK- and Austria-based biotech company developing novel therapies for life-threatening systemic fungal infections, announced today that the FDA has granted Breakthrough Therapy des...
Read More

Search Site

  Latest Jobs

Sign up to our Newsletter

Our Valued Sponsors & Partners